Nestor Prieto-Dominguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nestor Prieto-Dominguez has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Alisha Holtzhausen
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
62 shared publications - Angel Humphryes
Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama
62 shared publications - Eric Ubil
Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama
62 shared publications - Francesca Dempsey
Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama
62 shared publications - Henry Shelton Earp
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
62 shared publications - Katarina Moretto
Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama
62 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S24 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 24. Stat1 has two binding sites on the MyD88 promoter (proximal, distal) but tumor cell secretions do not affect association at the distal site.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S24 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 24. Stat1 has two binding sites on the MyD88 promoter (proximal, distal) but tumor cell secretions do not affect association at the distal site.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S15 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 15. The T cell population is reduced by cisplatin therapy and altered by BVT948 or combination therapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S15 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 15. The T cell population is reduced by cisplatin therapy and altered by BVT948 or combination therapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 9. Flow cytometry gating strategy to identify live CD45+ immune cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 9. Flow cytometry gating strategy to identify live CD45+ immune cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 5. Pros1 deficient tumors show reduced tumor growth after cisplatin treatment and increased immune activation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 5. Pros1 deficient tumors show reduced tumor growth after cisplatin treatment and increased immune activation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 4. PTP inhibitors have limited effects on tumor cell viability in vitro and increase angiogenesis associated pathways in vivo.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 4. PTP inhibitors have limited effects on tumor cell viability in vitro and increase angiogenesis associated pathways in vivo.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S23 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 23. Tumor cells do not suppress Stat1 expression in naïve macrophages.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S23 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 23. Tumor cells do not suppress Stat1 expression in naïve macrophages.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 8. Two doses of cisplatin in combination with BVT948 PTP inhibition substantially reduces B16F10 tumor growth.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 8. Two doses of cisplatin in combination with BVT948 PTP inhibition substantially reduces B16F10 tumor growth.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 3. BVT948 treatment of early GEMM6 tumors results in some durable responses and reduces growth when combined with vemurafenib in larger tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 3. BVT948 treatment of early GEMM6 tumors results in some durable responses and reduces growth when combined with vemurafenib in larger tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S17 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 17. Characterization of monocyte subsets in each treatment group identifies varied effects.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S17 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 17. Characterization of monocyte subsets in each treatment group identifies varied effects.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 10. Changes in tumor immune cell composition following respective treatments.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy
Supplemental Figure 10. Changes in tumor immune cell composition following respective treatments.